Antiplatelet agents for the treatment and prevention of coronary atherothrombosis
Antiplatelet drugs provide first-line antithrombotic therapy for the management of acute
ischemic syndromes (both coronary and cerebrovascular) and for the prevention of their …
ischemic syndromes (both coronary and cerebrovascular) and for the prevention of their …
[HTML][HTML] Platelet aggregometry testing: molecular mechanisms, techniques and clinical implications
K Koltai, G Kesmarky, G Feher, A Tibold… - International journal of …, 2017 - mdpi.com
Platelets play a fundamental role in normal hemostasis, while their inherited or acquired
dysfunctions are involved in a variety of bleeding disorders or thrombotic events. Several …
dysfunctions are involved in a variety of bleeding disorders or thrombotic events. Several …
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a …
D Sibbing, D Aradi, C Jacobshagen, L Gross, D Trenk… - The Lancet, 2017 - thelancet.com
Background Current guidelines recommend potent platelet inhibition with prasugrel or
ticagrelor for 12 months after an acute coronary syndrome managed with percutaneous …
ticagrelor for 12 months after an acute coronary syndrome managed with percutaneous …
Benefit of switching dual antiplatelet therapy after acute coronary syndrome according to on-treatment platelet reactivity: the TOPIC-VASP pre-specified analysis of the …
P Deharo, J Quilici, L Camoin-Jau, TW Johnson… - JACC: Cardiovascular …, 2017 - jacc.org
Objectives: This study sought to evaluate the impact of initial platelet reactivity on the benefit
of switched strategy. Background: TOPIC (Timing Of Platelet Inhibition after acute Coronary …
of switched strategy. Background: TOPIC (Timing Of Platelet Inhibition after acute Coronary …
Antithrombotic therapy for acute coronary syndrome: past, present and future
D Sibbing, DJ Angiolillo, K Huber - Thrombosis and …, 2017 - thieme-connect.com
Plaque erosions and ruptures are the histopathological hallmarks of arterial thrombus
formation in the coronary arteries. The clinical condition associated with this process is …
formation in the coronary arteries. The clinical condition associated with this process is …
Update on antithrombotic therapy after percutaneous coronary revascularisation
T Cuisset, FWA Verheugt, L Mauri - The Lancet, 2017 - thelancet.com
For relief of coronary obstruction, percutaneous coronary intervention has become a
standard-of-care procedure over the past 40 years. Nonetheless, optimal outcomes after …
standard-of-care procedure over the past 40 years. Nonetheless, optimal outcomes after …
[HTML][HTML] Tailored antiplatelet therapy in high-risk ACS patients treated with PCI stenting: lessons from the ANTARCTIC trial
N Messas, JF Tanguay… - Journal of thoracic …, 2017 - ncbi.nlm.nih.gov
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2017; 9 (5): E440-E443 jtd.
amegroups. com led to the concept of a therapeutic window for DAPT (ie, an “optimal” range …
amegroups. com led to the concept of a therapeutic window for DAPT (ie, an “optimal” range …
О возможности уменьшения интенсивности двойной антитромбоцитарной терапии в первый год после острого коронарного синдрома: что говорят …
ИС Явелов - Неотложная кардиология, 2017 - elibrary.ru
В обзоре представлены современные данные о возможностях замены сочетания
ацетилсалициловой кислоты с прасугрелом или тикагрелором на ее сочетание с …
ацетилсалициловой кислоты с прасугрелом или тикагрелором на ее сочетание с …